RegeneRX, GtreeBNT Provide Update on RGN-137 for Treatment of Epidermolysis Bullosa
News
RegeneRx Biopharmaceuticals announced a clinical trial update on RGN-137, an investigational therapy for the treatment of epidermolysis bullosa (EB). The update was provided by GtreeBNT, RegeneRx’s partner for the ... Read more